#USA #Robbins Geller #San Diego #Class Action #Medpace Holdings

Legal Notice for Medpace Holdings Investors

Medpace Holdings Inc. (NASDAQ: MEDP) is facing a class action lawsuit, and individuals who purchased shares during the specified period may want to join the initiative. This article explains the essential details about the class action opportunities and the implications for investors.

Overview of the Class Action Lawsuit

In a recently announced class action lawsuit orchestrated by Robbins Geller Rudman & Dowd LLP, investors who acquired Medpace common stock from April 22, 2025, to February 9, 2026, are encouraged to consider serving as lead plaintiffs. The lawsuit, titled Durbin v. Medpace Holdings Inc., No. 26-cv-00346 (S.D. Ohio), accuses Medpace and several executives of serious violations of the Securities Exchange Act of 1934.

Investors have a window until June 8, 2026, to submit their applications for lead plaintiff roles, making it a timely opportunity for those impacted by significant financial losses.

Allegations Against Medpace Holdings

The Durbin v. Medpace lawsuit claims that during the class period, Medpace made numerous misleading statements regarding its financial health. The core allegations indicate that:

• - Medpace overstated its projected book-to-bill ratio for the fourth quarter of 2025.
• - The company neglected to disclose critical impacts of cancellations affecting its book-to-bill ratio.
• - Statements made regarding the achievability of projected metrics were misleading, falsely reassuring investors about business stability.
• - Concerns about lack of diversity in the company's pre-backlog were downplayed.
• - Management insisted that growth trends were broad and not limited to a few studies.

The lawsuit notes that on February 9, 2026, Medpace revealed disappointing Q4 2025 results, showcasing a book-to-bill ratio of 1.04, starkly below prior expectations. This revelation resulted in a near 16% drop in Medpace stock values, supporting claims that misleading information led to investor losses.

Steps to Become a Lead Plaintiff

Under the Private Securities Litigation Reform Act of 1995, investors who suffered losses may apply to become lead plaintiffs. A lead plaintiff usually has the largest financial stake in the lawsuit and adequately represents the interests of the class.

• - To join, investors should collect all relevant documentation outlining their purchase of Medpace stock during the specified period.
• - Interested individuals can contact Robbins Geller attorneys Ken Dolitsky or Michael Albert at 800/851-7783 or [email protected].
• - Prospective lead plaintiffs can choose their own legal representation to guide the lawsuit.
• - Importantly, participation as a lead plaintiff is not a requirement to share in any future financial recovery from the lawsuit.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller is a renowned law firm specializing in investor rights and securities fraud litigation. With a track record that includes recovering significant amounts for investors, Robbins Geller ranks highly in class action lawsuit performance. In 2025, they secured $916 million for investors, further establishing their standing in the legal community.

For individuals looking to pursue justice for their financial losses from Medpace, engaging with Robbins Geller could be a definitive step toward potential recovery. Meanwhile, ongoing communications on the progression of this lawsuit should be closely monitored by current and former Medpace investors.

As the class action advances, updates and further instructions will likely be disseminated, contributing to transparency and guidance for all involved parties. Understandably, investors remain vigilant as they seek to navigate these challenging developments regarding Medpace Holdings Inc.